145040-37-5 Candesartan cilexetil AKSci J10436
Loading Please Wait...
  J10436    AKSci Reference Standard
Candesartan cilexetil
, >98% (HPLC)

CAS Number:145040-37-5
MDL Number:MFCD00871371
Purity:>98% (HPLC)
Spectra:LCMS, HPLC
Physical Form:White to beige powder
Melting Point:163-175°C
Long-Term Storage:Store long-term at 2-8°C

Solubility:DMSO: =15 mg/mL
Application(s):Specific nonpeptide Ang II receptor (ATR) antagonist
Form:Free Base


 Candesartan selectively blocks the binding of angiotensin II to AT1 in many tissues including vascular smooth muscle and the adrenal glands. This inhibits the AT1-mediated vasoconstrictive and aldosterone-secreting effects of angiotensin II and results in an overall decrease in blood pressure. Candesartan is greater than 10,000 times more selective for AT1 than AT2. Inhibition of aldosterone secretion may increase sodium and water excretion while decreasing potassium excretion.

[1]Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Yusuf S, Pocock S: Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003 Sep 6;362(9386):759-66.
[2] Mendis B, Page SR: Candesartan: widening indications for this angiotensin II receptor blocker? Expert Opin Pharmacother. 2009 Aug;10(12):1995-2007.
[3] Baguet JP, Barone-Rochette G, Neuder Y: Candesartan cilexetil in the treatment of chronic heart failure. Vasc Health Risk Manag. 2009;5(1):257-64. Epub 2009 Apr 8.



Signal Word

Hazard Statements
H361; H410

Precautionary Statements
P201; P202; P273; P281; P308+P313; P391; P405; P501

Current as of July 13, 2020

AKSci Reference Standards are high-purity, low-impurity compounds suitable for use as standards.

Download SDS

For research use only. Not for diagnostic or therapeutic use. Not for human use. AK Scientific, Inc. does not sell to individuals. If you are a first-time customer, please email for review at least two official business documents issued by your local jurisdiction, state/province, or country.


 APIs and Bioactives > Angiotensin Receptor Blockers